AstraZeneca's Imfinzi/Tremelimumab Combo Conquers HIMALAYA

Improves Overall Survival In Liver Cancer Patients

After the combination's success in the non-small cell lung cancer POSEIDON study, AstraZeneca's Imfinzi and tremelimumab could now be on the way to approval as a first-line treatment for hepatocellular carcinoma.

himalaya
Astrazeneca scales the heights in HCC trial • Source: Alamy

A combination of AstraZeneca PLC's PD-L1 inhibitor Imfinzi and its much-maligned investigational CTLA-4 inhibitor tremelimumab has sprung a very pleasant surprise by improving survival rates in liver cancer patients.

The UK major has unveiled topline results from the closely watched HIMALAYA Phase III study which showed that a single,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category